<DOC>
	<DOCNO>NCT00549042</DOCNO>
	<brief_summary>This study test experimental drug call OROS® hydromorphone hydrochloride ( HCl ) , daily opioid analgesic relieve pain . A large number clinical study conduct test drug . NMED-1077 still test approved Food Drug Administration ( FDA ) sale United States . OROS® hydromorphone HCl currently approve Europe treat chronic pain . The purpose study compare NMED-1077 placebo see NMED-1077 safe efficacious .</brief_summary>
	<brief_title>Study Test Effectiveness Controlled-Release OROS® Hydromorphone HCl Compared Placebo Patients With Chronic Low Back Pain</brief_title>
	<detailed_description />
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Low Back Pain</mesh_term>
	<mesh_term>Hydromorphone</mesh_term>
	<criteria>INCLUSION CRITERIA 1 . Patients must provide write consent participate study prior study procedure , must understand free withdraw study time . 2 . Patients speak , read , write , understand English , must able read understand consent form , complete studyrelated procedure , communicate study staff . 3 . Male female patient age 1875 year , inclusive . 4 . Documented diagnosis moderate severe chronic low back pain must present 5 . Patients classified nonneuropathic ( Class 1 2 ) neuropathic ( Class 3 , 4 , 5 6 ) LBP base Quebec Task Force Classification Spinal Disorders enrol study . 6 . Patients require daily schedule opioid analgesic low back pain least 2 month prior screen visit . 7 . Patients daily opioid requirement ≥ 60 mg oral morphine equivalent ( ≥ 12 mg hydromorphone ) , ≤ 320 mg morphine ( ≤ 64 mg hydromorphone ) per day within 2 month prior screen visit . 8 . Patients , Investigator 's opinion , stable dose ( ≥ 2 week ) prior analgesic ( opioid nonopioid ) prior screen visit . 9 . Female subject childbearing potential include tubal ligation surgery exclude experienced menstrual period minimum 2 year , must negative serum pregnancy test screen visit , must consent utilize medically acceptable method contraception throughout entire study period include washout period 1 week study complete . EXCLUSION CRITERIA 1 . Patients active diagnosis fibromyalgia , complex regional pain syndrome ( include reflex sympathetic dystrophy causalgia ) , acute spinal cord compression , severe progressive low extremity weakness numbness , bowel bladder dysfunction result cauda equina compression , diabetic amyotrophy , meningitis , diskitis , back pain secondary infection tumor , pain cause confirm suspected neoplasm . 2 . Patients undergone surgical procedure back pain within 6 month prior screen visit . 3 . Patients nerve plexus block , include epidural steroid injection facet block , within 1 month prior screen visit . 4 . Patients chronic pain condition , investigator 's opinion , would interfere assessment low back pain ( e.g. , osteoarthritis , rheumatoid arthritis , postherpetic neuralgia , pain associate diabetic neuropathy , migraine headache require opioid therapy ) . 5 . Patients involve active workman 's compensation insurance claim disability claim litigation relate back pain . 6 . Patients history use illicit drug abuse , abused opioids exhibit drug seek behavior within 5 year prior screen visit . 7 . Patients abused prescription medication alcohol within 5 year prior screen visit . ( See appendix 11 DSMIV criterion substance abuse . ) 8 . Patients positive alcohol drug abuse test 9 . Women pregnant ( indicated positive result serum pregnancy test administer screen visit ) , breast feeding , plan breast feed within 30 day prior screen visit . 10 . Patients demonstrate allergic reaction hypersensitivity opioids . 11 . Patients bowel movement within three day , bowel obstruction within 60 day , prior screen visit . 12 . Patients preexist severe narrow gastrointestinal tract secondary : prior gastrointestinal surgery ( e.g. , vagotomy , antrectomy , pyroloplasty , gastroplasty , gastrojejunostomy ) gastrointestinal disease result impaired gastrointestinal function ( e.g. , paralytic ileus , gastroparesis , inflammatory bowel disease , `` short gut '' syndrome due adhesion decrease transit time , past history peritonitis , cystic fibrosis , chronic intestinal pseudobstruction , Meckel diverticulum ) 13 . Patients major psychiatric condition ( e.g. , schizophrenia , major depression ) clinically significant anxiety depression define HADS score great 10 . 14 . Patients receive monoamine oxidase ( MAO ) inhibitor within 14 day prior screen visit . 15 . Patients clinically significant abnormal laboratory result clinical chemistry , hematology urinalysis define Appendix 9 , include serum glutamicoxaloacetic transaminase/aspartate aminotransferase ( AST ) serum glutamicpyruvic transaminase/alanine aminotransferase ( ALT ) ≥ 3.0 time upper limit reference range serum creatinine ≥ 2.0 mg/dL screening . 16 . Patients serious unstable intercurrent illness . 17 . Patients history uncontrolled seizure disorder . 18 . Patients increase intracranial pressure , mental cloud unknown etiology , coma , hypotension . 19 . Patients severe asthma , severe chronic obstructive pulmonary disease , disorder predisposes patient CO2 retention respiratory depression . 20 . Patients take investigational drug within 30 day prior screen visit currently enrol another investigational drug study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Back Pain</keyword>
	<keyword>Chronic Low Back Pain</keyword>
	<keyword>Chronic Back Pain</keyword>
	<keyword>Pain</keyword>
	<keyword>Chronic Pain</keyword>
</DOC>